MA52548A - Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches - Google Patents

Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches

Info

Publication number
MA52548A
MA52548A MA052548A MA52548A MA52548A MA 52548 A MA52548 A MA 52548A MA 052548 A MA052548 A MA 052548A MA 52548 A MA52548 A MA 52548A MA 52548 A MA52548 A MA 52548A
Authority
MA
Morocco
Prior art keywords
oytocin
diagrams
embryo implantation
dosage regimes
prevent mis
Prior art date
Application number
MA052548A
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Ernest Loumaye
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of MA52548A publication Critical patent/MA52548A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
MA052548A 2016-07-21 2017-07-20 Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches MA52548A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365147P 2016-07-21 2016-07-21
US201762527721P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
MA52548A true MA52548A (fr) 2021-05-26

Family

ID=59501409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052548A MA52548A (fr) 2016-07-21 2017-07-20 Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches

Country Status (15)

Country Link
US (1) US20190247361A1 (fr)
EP (2) EP3487493B1 (fr)
JP (2) JP7036791B2 (fr)
KR (2) KR20230165386A (fr)
CN (3) CN115590849A (fr)
AU (2) AU2017300026B2 (fr)
BR (1) BR112019001047A2 (fr)
CA (1) CA3031252A1 (fr)
ES (1) ES2898778T3 (fr)
IL (1) IL264243B2 (fr)
MA (1) MA52548A (fr)
MX (1) MX2019000498A (fr)
SG (1) SG11201900461UA (fr)
UA (1) UA127283C2 (fr)
WO (1) WO2018015497A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220075340A (ko) * 2019-09-03 2022-06-08 옵스에파 에스에이 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투여 요법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780725A (en) 1971-03-04 1973-12-25 Smith Kline Instr Fetal heartbeat monitoring system with plural transducers in one plane and at different angles thereto
NL7511109A (nl) 1974-11-11 1976-05-13 Carter Wallace Werkwijze en middel voor het vaststellen van hor- moon in waterig milieu, in het bijzonder voor zwangerschapsonderzoek.
IL56342A (en) 1978-12-29 1982-05-31 Zer Tamar Method and means for determining human chorionic gonadotropin in urine
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
US4437467A (en) 1981-12-11 1984-03-20 American Home Products Corporation Apparatus for monitoring fetal heartbeat and the like
US4504469A (en) 1982-12-21 1985-03-12 Ferring Ab Vasotocin derivatives
US4720455A (en) 1985-09-06 1988-01-19 Pitman-Moore, Inc. Progesterone assay method for mammals and monoclonal antibody therefor
AU6417790A (en) 1989-09-22 1991-04-18 Tsi-Madison Research Institute Method and compositions for one-step cryopreservation of embryos
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
US6376743B1 (en) 1998-08-11 2002-04-23 University Of Hawaii Mammalian transgenesis by intracytoplasmic sperm injection
IL160780A0 (en) 2001-09-12 2004-08-31 Applied Research Systems USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
AU2003211011A1 (en) 2002-02-27 2003-09-09 Ferring Bv Intermediates and methods for making heptapeptide oxytocin analogues
EA009371B1 (ru) 2002-06-07 2007-12-28 Арес Трейдинг С.А. Способ управляемой гиперстимуляции яичников и фармацевтический набор для использования в таком способе
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
JP4722844B2 (ja) 2003-07-07 2011-07-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストとしてのピリミジン−２，４−ジオン誘導体
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
PL1879572T3 (pl) * 2005-05-10 2011-10-31 Ferring Bv Zastosowanie antagonistów oksytocyny i/lub wazopresyny we wspomaganym rozrodzie
WO2008051620A2 (fr) 2006-10-24 2008-05-02 University Of Hawaii Methodes et compositions de transgenese par injection intracytoplasmique de spermatozoides
US7989217B2 (en) 2007-03-29 2011-08-02 Ameritek Usa, Inc. Method for determining hCG levels in fluid samples
WO2010011766A1 (fr) 2008-07-23 2010-01-28 Mariposa Biotechnology, Inc. Système automatisé de cryoconservation d'ovocytes, d'embryons ou de blastocystes
US9201077B2 (en) * 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
US8716286B2 (en) 2009-10-30 2014-05-06 Glaxo Group Limited Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
WO2013158658A1 (fr) 2012-04-16 2013-10-24 Cornell University Système de fertilisation assistée par injection intracytoplasmique automatisée de sperme
US8937139B2 (en) 2012-10-25 2015-01-20 Chevron Phillips Chemical Company Lp Catalyst compositions and methods of making and using same
WO2014080032A1 (fr) * 2012-11-26 2014-05-30 Ferring B.V. Procédé et système pour le diagnostic de niveaux de contraction utérine à l'aide d'une analyse d'image
EP2845850A1 (fr) 2013-09-10 2015-03-11 ObsEva S.A. Dérivés de pyrrolidine comme antagonistes des récepteurs V1a de vasopressine/oxytocine
EP2886107A1 (fr) 2013-12-17 2015-06-24 ObsEva S.A. Formules orales de dérivés de pyrrolydine
ES2774789T3 (es) * 2014-07-02 2020-07-22 ObsEva SA O-Metiloxima de (3Z,5S)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil]pirrolidin-3-ona cristalina útil en métodos de tratamiento de estados relacionados con la actividad del OT-R
EP3501533A1 (fr) * 2014-12-22 2019-06-26 Ferring B.V. Thérapie par antagoniste du récepteur de l'oxytocine dans la phase lutéinique pour l'implantation et la grossesse chez les femmes subissant des technologies de reproduction assistée
JP2018535946A (ja) 2015-10-06 2018-12-06 フェリング・ベー・フェー バルシバン及びその中間体を作製する新規の方法

Also Published As

Publication number Publication date
CN109689048A (zh) 2019-04-26
AU2017300026B2 (en) 2023-07-13
SG11201900461UA (en) 2019-02-27
BR112019001047A2 (pt) 2019-04-30
IL264243B (en) 2022-10-01
JP2022078194A (ja) 2022-05-24
UA127283C2 (uk) 2023-07-12
AU2017300026A1 (en) 2019-02-28
CA3031252A1 (fr) 2018-01-25
KR20190039725A (ko) 2019-04-15
CN109689048B (zh) 2022-10-28
EP3487493B1 (fr) 2021-09-01
ES2898778T3 (es) 2022-03-08
KR20230165386A (ko) 2023-12-05
JP2019523251A (ja) 2019-08-22
WO2018015497A2 (fr) 2018-01-25
IL264243B2 (en) 2023-02-01
CN115590849A (zh) 2023-01-13
US20190247361A1 (en) 2019-08-15
EP3487493A2 (fr) 2019-05-29
CN115569132A (zh) 2023-01-06
MX2019000498A (es) 2019-09-16
AU2023237170A1 (en) 2023-10-19
JP7036791B2 (ja) 2022-03-15
WO2018015497A3 (fr) 2018-03-01
IL264243A (en) 2019-02-28
EP4056178A1 (fr) 2022-09-14

Similar Documents

Publication Publication Date Title
MA44007A (fr) Inhibiteurs du récepteur interagissant avec protéine kinase 1
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
SG10201913902RA (en) Antibody agents specific for human cd19 and uses thereof
MA52308A (fr) Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MA44391A (fr) Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
MA39479A (fr) Structure prosthetique d'implant dentaire
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
RS59613B1 (sr) Muskarinski antagonisti i njihove kombinacije za lečenje bolesti disajnih puteva kod konja
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
IT201600078872A1 (it) Olio e dispositivo per l'igiene dell'area oculare e perioculare
MA52548A (fr) Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL251024A0 (en) Antibodies against eutaxin 2 for use in the treatment of liver diseases
IT201600122310A1 (it) Composizione per uso nella terapia di alterazioni dell'intestino
LT3258920T (lt) Kieta farmacinė dozavimo forma, tinkanti tirpinti geriamajame vandenyje ir vartoti kaip geriamąjį vaistinį tirpalą
GB201902996D0 (en) Animal footbath appparatus
EP3829626C0 (fr) Extrait de lespedeza capitata pour son utilisation dans le domaine capillaire
MA46291A (fr) Agents anti-cancéreux et leur préparation
MA43834A (fr) Combinaison pour traiter la douleur
FR3019987B1 (fr) Composition cosmetique comprenant un melange de miels et du nectar de kniphofia